Análisis comparativo de un grupo de pacientes con narcolepsia-cataplejía, narcolepsia sin cataplejía e hipersomnia idiopática

Martínez-Rodríguez, José Enrique; Iranzo, Álex; Casamitjana, Roser; Graus, Francesc; Santamaría, Joan

doi:10.1157/13099970

Cited by 8 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials using intravenous immunoglobulin infusions in recent onset narcolepsy with cataplexy have led to improvement in cataplexy in some patients [11]. Despite the fact that specific antibody markers for narcolepsy are still elusive, an autoimmune-mediated mechanism is considered the most probable etiology for narcolepsy and the elucidation of immune markers is one of the top priorities in narcolepsy research [12], [13]. A number of studies have focused on cytokines.…”

Section: Introductionmentioning

confidence: 99%

Elevated Peripheral Visfatin Levels in Narcoleptic Patients

Dahmen¹,

Manderscheid²,

Helfrich³

et al. 2008

PLoS ONE

View full text Add to dashboard Cite

ObjectiveNarcolepsy is a severe sleep disorder that is characterized by excessive daytime sleepiness, cataplexies and a tendency towards obesity. Recent discoveries indicate that the major pathophysiology is a loss of hypocretin (orexin) producing neurons due to immunologically mediated degeneration. Visfatin is a recently described proinflammatory adipokine. It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF). Our study examines the hypothesis that visfatin levels are altered in narcoleptic patients.MethodsFor the analysis, a total of n = 54 patients (n = 18 males and n = 36 females) with the diagnosis of narcolepsy according to DSM-IV and the International Classification of Sleep Disorders were examined (BMI mean 30.3±5.5, age mean 52.5±16.1 years). As a control group 39 unrelated (n = 12 males and n = 27 females) healthy volunteers with no sleep disorder according to DSM-IV were included (BMI mean 28.5±4.6, age mean 51.1±13.6 years). Peripheral visfatin levels were measured using a commercial enzyme immunoassay kit with a measurement range from 0.1–1000 ng/ml. Narcolepsy symptoms, severity and frequency of symptoms as well as the total duration of various aspects of the symptomatology were assessed by unstructured and structured clinical interviews in including the Stanford Center for Narcolepsy Sleep Inventory.ResultsCirculating visfatin was found to be significantly increased in HLA DR2 positive narcoleptic patients compared to controls.ConclusionTaken together, our results add to the evidence of disturbed immunological regulation in patients with narcolepsy.

show abstract

Section: Introductionmentioning

confidence: 99%